Lexaria Bioscience
LEXX
11 hedge funds and large institutions have $2.83M invested in Lexaria Bioscience in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
0.68% more ownership
Funds ownership: 8.18% → 8.86% (+0.68%)
3% less capital invested
Capital invested by funds: $2.93M → $2.83M (-$97K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$226K |
| 2 |
VF
Virtu Financial
New York
|
+$76.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.1K |
| 4 |
Morgan Stanley
New York
|
+$6.39K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$120K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$8.84K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$26 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ICM
1
Invenomic Capital Management
Boston,
Massachusetts
| $2.21M | +$226K | +35,309 | +11% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $306K | -$8.84K | -1,383 | -3% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $193K | +$31.1K | +4,858 | +19% |
|
|
VF
4
Virtu Financial
New York
| $75K | +$76.4K | +11,941 | New |
|
|
EWM
5
Edge Wealth Management
New York
| $21K | – | – | – |
|
|
MFM
6
MD Financial Management
Ottawa,
Ontario, Canada
| $17K | – | – | – |
|
|
7
Morgan Stanley
New York
| $6K | +$6.39K | +1,000 | New |
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | +$895 | +140 | +55% |
|
|
9
Osaic Holdings
Scottsdale,
Arizona
| $2K | +$1.28K | +200 | +118% |
|
|
10
Renaissance Technologies
New York
| – | -$120K | -17,200 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$2K | -251 | Closed |
|
|
12
Wells Fargo
San Francisco,
California
| – | -$26 | -4 | -14% |
|
|
GCM
13
Gables Capital Management
Miami,
Florida
| – | +$83 | +13 | New |
|
LEXX Hedge Fund Activity: Q3 2021 in Review
11 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q3 2021, worth a combined $2.83M — down 3.3% from $2.93M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LEXX positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Invenomic Capital Management, adding an estimated $226K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $120K sold.
- 11 institutional investors held Lexaria Bioscience (LEXX) as of Q3 2021, up from 10 in Q2 2021.
- Funds reported $2.83M of Lexaria Bioscience stock for Q3 2021, down 3.3% quarter-over-quarter.
- 3 funds opened new Lexaria Bioscience positions in Q3 2021 and 2 closed out, a net change of +1 holder.
- The largest Lexaria Bioscience buyer in Q3 2021 was Invenomic Capital Management, an estimated $226K added.
- The largest Lexaria Bioscience seller in Q3 2021 was Renaissance Technologies, an estimated $120K sold.
Based on aggregated 13F filings for Q3 2021.